Physician profile
Daniela Maxim
NPI 1962892307
$111,559.91
in general payments reported to CMS, 2019-2025
30 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $20K · 2023: $28K · 2024: $30K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Food and Beverage: $14K · Travel and Lodging: $6,010 · Consulting Fee: $1,560 · Education: $700 · Honoraria: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,310.00 |
| Food and Beverage | $14,136.83 |
| Travel and Lodging | $6,010.29 |
| Consulting Fee | $1,560.00 |
| Education | $699.85 |
| Honoraria | $251.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $64,814.89 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $19,079.22 | 2021-2025 | |
| Galderma Laboratories, L.P. | $13,907.98 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $2,609.74 | 2021-2025 | Tremfya, Stelara, Simponi |
| Leo Pharma INC. | $1,779.75 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $1,596.27 | 2021-2025 | Winlevi, Absorica Ld |
| Ucb, INC. | $1,333.71 | 2021-2025 | Bimzelx |
| Abbvie INC. | $1,244.23 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $901.63 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $803.62 | 2022-2025 | Sotyktu |
| Incyte Corporation | $706.06 | 2021-2025 | Opzelura |
| Pfizer INC. | $461.82 | 2021-2025 | |
| Dermavant Sciences, INC. | $407.90 | 2022-2024 | Vtama |
| Amgen INC. | $389.46 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $313.41 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $209.94 | 2021-2025 | |
| Journey Medical Corporation | $187.36 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.52 | 2021-2023 | Siliq |
| Lilly USA, LLC | $140.39 | 2022-2025 | Olumiant, Ebglyss, Taltz |
| Vyne Pharmaceuticals INC. | $119.70 | 2021 | |
| Organon LLC | $87.76 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $54.90 | 2023-2025 | |
| Almirall LLC | $53.87 | 2021-2022 | |
| Krystal Biotech INC | $45.58 | 2025 | Vyjuvek |
| Epi Health, LLC | $26.28 | 2022 | |
| Cordis US Corp. | $25.43 | 2025 | Mynxgrip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.56 | 2024 | Spevigo |
| Botanix Sb INC | $19.32 | 2025 | Sofdra |
| Biofrontera INC. | $17.16 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.45 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Maxim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.